Eli Lilly announced on “Good Morning America” Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new multi-dose KwikPen, giving patients a simpler way to receive a full month of treatment in one device.
The Food and Drug Administration approved a label expansion allowing Zepbound to be delivered through the four-dose, single-patient KwikPen, which provides four once-weekly injections without the need for syringes.
Weight loss drugs including Zepbound, Wegovy in shortage, FDA says
The pen has been used by millions of patients worldwide for other Lilly medications, according to the company.
The new Zepbound KwikPen will be available beginning Feb. 23 to eligible self-pay patients who receive prescriptions through LillyDirect, the company’s direct-to-consumer platform.
Patients will be able to choose between the multi-dose pen or the existing single-dose vials at the same self-pay price, starting at $299 per month for the 2.5 mg starter dose.
Scott Olson/Getty Images – A sign with the company logo sits on the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.
Zepbound, which contains the active ingredient tirzepatide, was the most prescribed weight management medication in 2025, Lilly said.
In clinical trials, adults taking Zepbound lost an average of up to 20.9% of their body weight over 72 weeks, compared with 3.1% among those taking a placebo.
In another study comparing Zepbound to injectable Wegovy, participants taking Zepbound lost an average of about 50 pounds, compared with 33 pounds for those taking Wegovy.
The medication is FDA-approved to help adults with obesity — or adults with overweight and also have weight-related medical conditions — lose weight and keep it off when used alongside diet and exercise.
Eli Lilly to sell Zepbound directly to consumers without insurance coverage
Zepbound is also approved to help adults with moderate-to-severe obstructive sleep apnea and obesity improve their symptoms.
Lilly said more than 1 million patients accessed treatments through LillyDirect in 2025, with strong demand for Zepbound among people paying out of pocket. The company said the addition of the KwikPen is intended to expand choice and allow patients and health care providers to select the option that best fits individual needs and preferences.
Doctors caution that Zepbound is not for cosmetic weight loss and should only be used after a medical evaluation.
Common side effects can include nausea, vomiting, diarrhea, abdominal pain, indigestion, fatigue and heartburn. More serious risks, including thyroid tumors and pancreatitis, are also listed in the drug’s safety warnings.
Zepbound is manufactured by Eli Lilly and should be used only under the guidance of a health care provider.
What to know about the Zepbound KwikPen
What it is:
A multi-dose KwikPen delivering four weekly injections in one device.
Who can get it:
Self-pay patients with a prescription through LillyDirect.
Cost:
Starts at $299 per month for the 2.5 mg starter dose.
Other options:
Patients can still choose single-dose vials at the same price.
A similar drug known as Wegovy is available in pen or pill form and sold by Novo Nordisk.
What it treats:
Obesity, some cases of overweight with medical conditions, and obstructive sleep apnea.
Important note:
Must be used with diet and exercise and after medical screening.
